

AMENDMENTS TO THE CLAIMS

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1-179. (Canceled)

180. (New) An isolated polypeptide with a sequence as set forth as SEQ ID NO: 55 or a fragment thereof that is at least 8 amino acids in length.

181. (New) The isolated polypeptide of claim 180, wherein the fragment is at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 75 or 100 amino acids in length.

182. (New) A composition comprising the isolated polypeptide of claim 180 or 181 and a pharmaceutically acceptable carrier.

183. (New) The composition of claim 182, wherein the composition further comprises an adjuvant.

184. (New) The composition of claim 182, wherein the composition further comprises a cytokine.

185. (New) The composition of claim 182, wherein the composition further comprises a costimulatory molecule.

186. (New) The composition of claim 182, wherein the composition further comprises a MHC molecule, and wherein the isolated polypeptide is complexed to the MHC molecule.

187. (New) The composition of claim 186, wherein the MHC molecule is a HLA class I molecule.

188. (New) The composition of claim 186, wherein the MHC molecule is a HLA class II molecule.

189. (New) A kit for detecting antibodies reactive to a sarcoma-associated antigen in a biological sample, comprising:

one or more sarcoma-associated antigens with a sequence as set forth as SEQ ID NO: 55 or a fragment thereof that is at least 8 amino acids in length, and

instructions for the use of the sarcoma-associated antigens in the detection of antibodies in the biological sample.

190. (New) The kit of claim 189, wherein the fragment is at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 75 or 100 amino acids in length.

191. (New) The kit of claim 189 or 190, wherein the sarcoma-associated antigen is bound to a substrate.